文献速递前列腺癌

4Kscore与SelectMDx在前列腺穿刺决策及前列腺癌检测中的一致性与性能比较

Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.
PubMed 文献 · Urology · 2020-04-12

本研究比较了4Kscore与SelectMDx在指导前列腺穿刺决策中的一致性及检测临床显著前列腺癌(csPCa)的性能。128例连续转诊患者中114例同时接受两种检测,两种生物标志物在7.5%和12%阈值下一致性差(kappa分别为0.184和0.22),穿刺指导不一致率分别为46%和38%。

要点

  • 4Kscore与SelectMDx在穿刺决策上一致性差,不一致率高达46%和38%。
  • 4Kscore联合MRI检测csPCa的AUC为0.830,显著优于SelectMDx的0.672。
  • 两者不一致性提示需前瞻性比较研究优化生物标志物在前列腺穿刺选择中的应用。

核心结论

  • 4Kscore与SelectMDx在指导前列腺穿刺决策上不一致性令人担忧。
  • 4Kscore联合MRI检测csPCa的性能优于SelectMDx。
  • 需前瞻性比较研究优化生物标志物用于选择前列腺穿刺候选人。

研究设计与样本

  • 2018年11月至2019年4月连续转诊的PSA升高患者被建议同时接受4Kscore和SelectMDx检测以指导穿刺选择。
  • 128例连续转诊患者中114例(89.1%)接受了两种检测。
  • 若生物标志物检测csPCa风险≥7.5%或MRI PI-RADS≥1则建议行前列腺穿刺。
  • 采用Cohen's Kappa评估两种检测二分类结果的一致性,外部验证阈值分别为7.5%和12%。
  • 采用ROC曲线及AUC评估各生物标志物区分csPCa的性能。

主要发现

  • 7.5%阈值下两种生物标志物的kappa系数为0.184(一致性差),12%阈值下为0.22。
  • 两种生物标志物在是否行前列腺穿刺的指导上分别有46%和38%的病例不一致。
  • 50例接受前列腺穿刺的患者中22例(44%)发现csPCa。
  • 4Kscore检测csPCa的AUC为0.830(95%CI:0.710-0.949)。

关键数值与推荐

  • 穿刺建议阈值:生物标志物报告csPCa风险≥7.5%或MRI PI-RADS≥1。
  • 一致性评估阈值:7.5%和12%。
  • 4Kscore检测csPCa的AUC为0.830(95%CI:0.710-0.949)。
  • 两种检测在7.5%阈值下kappa=0.184,12%阈值下kappa=0.22。

临床怎么用

  • 4Kscore联合MRI可用于指导前列腺穿刺选择,其检测csPCa性能优于SelectMDx。
  • 鉴于两种生物标志物指导决策不一致率高,临床选择生物标志物时需注意其差异。
  • SelectMDx在本研究中区分csPCa性能较低,单独用于穿刺决策需谨慎。

局限性

  • 本研究为单中心连续转诊队列,样本量有限(114例接受检测)。
  • 仅50例患者接受了前列腺穿刺,穿刺率可能受选择偏倚影响。
  • 需前瞻性比较研究进一步验证并优化生物标志物的临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare both the concordance between the 4Kscore and SelectMDx for informing decision to perform prostate biopsy (PB) and the performance of these tests for detecting clinically significant prostate cancer (csPCa). Several biomarkers were developed to inform decisions whether to perform a PB based on the probability of detecting csPCa. There is a paucity of studies directly comparing them METHODS: Between 11/2018 and 4/2019, all new referrals with the diagnosis of elevated PSA were advised to undergo 4Kscore and SelectMDx in order to guide the selection of candidates for PB. Men were advised to undergo PB if the reported biomarker risk for detecting csPCA was ≥7.5%, or if they presented a Prostate Image Reporting and Data System ≥1 MRI. Cohen's Kappa was used to assess the concordance between the binary 4Kscore and SelectMDx results using externally validated cutoffs of 7.5% and 12%. Receiver operating characteristics curve and area under the curve (AUC) assessed the performance of each biomarker for distinguishing csPCa. RESULTS: Of 128 consecutive patients referred, 114 (89.1%) underwent 4Kscore and SelectMDx. The kappa coefficient between the biomarkers using the 7.5% cutoff was 0.184 (poor concordance) and 0.22 using the 12% cutoff. The two biomarkers yielded discordant guidance whether to proceed with PB in 46% and 38% of cases, respectively. csPCa was found in 22 of the 50 patients who underwent PB (44%). The AUC for 4Kscore and SelectMDx was 0.830 (95% confidence interval [CI]: 0.710 - 0.949) and 0.672 (95%CI: 0.517 - 0.828; P = .036) for csPCa, respectively. CONCLUSION: The discordance observed between the 4Kscore and SelectMDx is disconcerting. The 4Kscore when combined with magnetic resonance imaging was superior to the SelectMDx for detecting csPCa. Prospective comparative studies must be performed to optimize implementation of biomarkers for selecting candidates for PB.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Wysock JS, Becher E, Persily J, et al. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. Urology. 2020. PMID: 32294481. doi:10.1016/j.urology.2020.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。